Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elisabetta Bersellini is active.

Publication


Featured researches published by Elisabetta Bersellini.


Drug Safety | 2003

Patients understanding of risk associated with medication use: Impact of European Commission guidelines and other risk scales.

Dianne C. Berry; David K. Raynor; Peter Knapp; Elisabetta Bersellini

Patients want and need comprehensive and accurate information about their medicines so that they can participate in decisions about their healthcare. In particular, they require information about the likely risks and benefits that are associated with the different treatment options. However, to provide this information in a form that people can readily understand and use is a considerable challenge to healthcare professionals. One recent attempt to standardise the language of risk has been to produce sets of verbal descriptors that correspond to specific probability ranges, such as those outlined in the European Commission (EC) Pharmaceutical Committee guidelines in 1998 for describing the incidence of adverse effects.This paper provides an overview of a number of studies involving members of the general public, patients, and hospital doctors, that evaluated the utility of the EC guideline descriptors (very common, common, uncommon, rare, very rare). In all studies it was found that people significantly over-estimated the likelihood of adverse effects occurring, given specific verbal descriptors. This in turn resulted in significantly higher ratings of their perceived risks to health and significantly lower ratings of their likelihood of taking the medicine. Such problems of interpretation are not restricted to the EC guideline descriptors. Similar levels of misinterpretation have also been demonstrated with two other recently advocated risk scales (Calman’s verbal descriptor scale and Barclay, Costigan and Davies’ lottery scale).In conclusion, the challenge for risk communicators and for future research will be to produce a language of risk that is sufficiently flexible to take into account different perspectives, as well as changing circumstances and contexts of illness and its treatments. In the meantime, we urge the EC and other legislative bodies to stop recommending the use of specific verbal labels or phrases until there is a stronger evidence base to support their use.


Psychology & Health | 2002

Communicating Information About Medication Side Effects: Effects on Satisfaction, Perceived Risk to Health, and Intention to Comply

Dianne C. Berry; Irene C. Michas; Elisabetta Bersellini

Previous research has shown that peoples evaluations of explanations about medication and their intention to comply with the prescription are detrimentally affected by the inclusion of information about adverse side effects of the medication. The present study (Experiment 1) examined which particular aspects of information about side effects (their number, likelihood of occurrence, or severity) are likely to have the greatest effect on peoples satisfaction, perception of risk, and intention to comply, as well as how the information about side effects interacts with information about the severity of the illness for which the medication was prescribed. Across all measures, it was found that manipulations of side effect severity had the greatest impact on peoples judgements, followed by manipulations of side effect likelihood and then number. Experiments 2 and 3 examined how the severity of the diagnosed illness and information about negative side effects interact with two other factors suggested by Social Cognition models of health behaviour to affect peoples intention to comply: namely, perceived benefit of taking the prescribed drug, and the perceived level of control over preventing or alleviating the side effects. It was found that providing people with a statement about the positive benefit of taking the medication had relatively little effect on judgements, whereas informing them about how to reduce the chances of experiencing the side effects had an overall beneficial effect on ratings.


Psychology & Health | 2003

Communicating Information About Medication: The Benefits of Making it Personal

Dianne C. Berry; Irene C. Michas; Elisabetta Bersellini

Two experiments, using a controlled empirical methodology, investigated the effects of presenting information about medicines using a more personalised style of expression. In both studies, members of the general public were given a hypothetical scenario about visiting the doctor, being diagnosed with a particular illness, and being prescribed a medication. They were also given a written explanation about the medicine and were asked to provide ratings on a number of measures, including satisfaction, perceived risk to health, and intention to comply. In Experiment 1 the explanation focused only on possible side effects of the medicine, whereas in Experiment 2 a fuller explanation was provided, which included information about the illness, prescribed drug, its dosage and contraindications as well as its side effects. In both studies, use of a more personalised style resulted in significantly higher ratings of satisfaction and significantly lower ratings of likelihood of side effects occurring and of perceived risk to health. In Experiment 2 it also led to significantly improved recall for the written information.


Psychology & Health | 2007

The benefits of providing benefit information: Examining the effectiveness of provision of simple benefit statements on people's judgements about a medicine

Elisabetta Bersellini; Dianne C. Berry

Three experiments examined the effects of adding information about medication benefits to a short written explanation about a medicine. Participants were presented with a fictitious scenario about visiting the doctor, being prescribed an antibiotic and being given information about the medicine. They were asked to make various judgements relating to the information, the medicine and their intention to take it. Experiment 1 found that information about benefits enhanced the judgements, but did not influence the intention to comply. Experiment 2 compared the relative effectiveness of two different forms of the benefit statement, and found that both were effective in improving judgements, but had no effect on intention to comply. Experiment 3 compared the effectiveness of the two forms of benefit information but participants were told that the medicine was associated with four named side effects. Both types of statement improved ratings of the intention to comply, as well as ratings on the other measures. The experiments provide fairly consistent support for the inclusion of benefit information in medicine information leaflets, particularly to balance concerns about side effects.


International Journal of Pharmacy Practice | 2007

The benefits of providing benefit information in a patient information leaflet

Elisabetta Bersellini; Diane C. Berry

Objective To examine the effects of providing two different types of written information about medicine benefits in a patient information leaflet (PIL).


Journal of Clinical Nursing | 2006

Attitudes towards, and information needs in relation to, supplementary nurse prescribing in the UK: an empirical study

Dianne C. Berry; Molly Courtenay; Elisabetta Bersellini


Patient Education and Counseling | 2004

Over the counter medicines and the need for immediate action: a further evaluation of European Commission recommended wordings for communicating risk

Dianne C. Berry; Theo Raynor; Peter Knapp; Elisabetta Bersellini


Rheumatology | 2004

Perceptions of the risks and benefits of medicines in patients with rheumatoid arthritis and other painful musculoskeletal conditions.

Dianne C. Berry; A. Bradlow; Elisabetta Bersellini


International Journal of Pharmacy Practice | 2004

Interpretation of recommended risk terms: differences between doctors and lay people

Dianne C. Berry; Wendy Holden; Elisabetta Bersellini


Contraception | 2002

Official warnings on thromboembolism risk with oral contraceptives fail to inform users adequately

Dianne C. Berry; David K. Raynor; Peter Knapp; Elisabetta Bersellini

Collaboration


Dive into the Elisabetta Bersellini's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wendy Holden

Nuffield Orthopaedic Centre

View shared research outputs
Researchain Logo
Decentralizing Knowledge